Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01364259 · ClinicalTrials.gov registry record · Phase 3
A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia
A Phase 3 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT01364259: Clinical Trial Phase 3 study, sponsored by Stanford University.
NCT01364259 is a Phase 3 study that was terminated before completion, run by Stanford University. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01364259, a Phase 3 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
Trigeminal neuralgia or tic douloureux is severe, often debilitating, facial pain that significantly impairs the patient's quality of life and health. Stereotactic radiosurgery has been shown to provide pain relief in majority of patients treated. However, a common side effect of radiosurgery is facial numbness. Our goal is to maximize pain control while minimizing side effects. To this end, the purpose of this study is to evaluate whether adding a drug, amifostine, at the time of radiosurgery will protect patients from facial numbness.
Interventions
- DRUG Amifostine
- PROCEDURE CyberKnife stereotactic radiosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-09 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01364259
The ClinicalTrials.gov registry entry for NCT01364259 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Amifostine is the first listed.
NCT01364259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01364259 about?
NCT01364259 is a clinical study titled "A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia". Trigeminal neuralgia or tic douloureux is severe, often debilitating, facial pain that significantly impairs the patient's quality of life and health. Stereotactic radiosurgery has been shown to provide pain relief in majority of patients treated. However, a common side effect of radiosurgery is fac...
What is the current status of trial NCT01364259?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2008-09. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01364259?
The interventions under investigation include: Amifostine (DRUG), CyberKnife stereotactic radiosurgery (PROCEDURE).
Who is sponsoring clinical trial NCT01364259?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.